AstraZeneca PLC — Investor Relations & Filings
AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 425 Filing | 2021-02-26 | English | |
| 425 Filing | 2021-02-25 | English | |
| VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US | 2021-02-22 | English | |
| Voluntary withdrawal Imfinzi US bladder indication | 2021-02-22 | English | |
| F-4 | 2021-02-19 | English | |
| LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA | 2021-02-17 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2021
15 filings
| |||||
| 25471828 | 425 Filing | 2021-02-26 | English | ||
| 25472116 | 425 Filing | 2021-02-25 | English | ||
| 10017860 | VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US | 2021-02-22 | English | ||
| 1275085 | Voluntary withdrawal Imfinzi US bladder indication | 2021-02-22 | English | ||
| 10017861 | F-4 | 2021-02-19 | English | ||
| 10017862 | LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA | 2021-02-17 | English | ||
| 1273433 | Lynparza: IDMC recommend early analysis of OlympiA | 2021-02-17 | English | ||
| 10017863 | IRANNOTICE | 2021-02-16 | English | ||
| 10017864 | FILING OF FORM 20-F WITH SEC | 2021-02-16 | English | ||
| 10017867 | DIRECTOR/PDMR SHAREHOLDING | 2021-02-16 | English | ||
| 10017865 | ANNUAL FINANCIAL REPORT | 2021-02-16 | English | ||
| 1272789 | Filing of Form 20-F with SEC | 2021-02-16 | English | ||
| 10017866 | 20-F | 2021-02-16 | English | ||
| 1272031 | Director/PDMR Shareholding | 2021-02-15 | English | ||
| 1272268 | AstraZeneca PLC Annual Report and Form 20-F Information 2020 | 2021-02-15 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for AstraZeneca PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
AstraZeneca PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/5229/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=5229 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=5229 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=5229 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 5229}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for AstraZeneca PLC (id: 5229)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.